5 things to know about psoriasis - Fort Worth Star Telegram
5 things to know about psoriasisFort Worth Star Telegram, TX - Apr 27, 2008By MADELEINE MARR 1What it is: Psoriasis is a chronic immune system-related disorder that occurs when the skin replaces itself too quickly. …
Duke Pushing to New Psoriasis Treatments - WRAL.com
Duke Pushing to New Psoriasis TreatmentsWRAL.com, NC - 8 hours agoDurham, NC — Psoriasis ranks alongside heart failure and diabetes among surveys that contrast the effect of illnesses on quality of life. …
What to do about Scalp Psoriasis
Often psoriasis that attacks the scalp can result in hair loss, although it is most often temporary. Either hair loss or psoriasis can be traumatic, but put both together and you might feel like life as you know it has just ended. …
What Caused Sudden Female Hair Loss — Chemical Relaxer or Psoriasis?
A client I have serviced for almost one year accuses me of causing her hair to fall out after a relaxer I gave her. She called me two days after the relaxer saying her hair was shedding. I am very thorough with my rinsing of chemicals …
Psoriasis treatment:how to cure psoriasis effective?
Psoriasis is a common skin disease that has multiple forms. Yet most of the types of psoriasis have common traits that run through.
Psoriasis And Sunlight
Although doctors choose treatments based on the type and severity of psoriasis and the areas of skin affected, the traditional approach is to start with the mildest treatments - topical creams and ultraviolet light therapy …
Isotechnika’s Strategic Partner to Highlight Both Topical and Polymer Delivery Technologies Utilizing Voclosporin (CNW Group via Yahoo! Finance)
TSX:ISA) - Isotechnika Inc. announced today that collaborators with Lux Biosciences, Inc. are scheduled to present data on the use of voclosporin with Lux’s proprietary topical and new bioerodible polymer/drug products for the treatment of dry eye and other inflammatory eye diseases.
KaloBios Completes Patient Dosing in its U.S. Phase 1 Trial of Its Third Drug Candidate, KB003 (Business Wire via Yahoo! Finance)
PALO ALTO, Calif.—-KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced that the company has completed dosing subjects in a U.S. Phase 1 clinical trial of its third drug candidate, KB003.
MorphoSys Announces Completion of First Dosing in Phase 1 Trial for MOR103 Program (n-tv.de)
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced the completion of a first dosing regimen in a phase 1 clinical study on healthy volunteers of the HuCAL-derived antibody MOR103 with no adverse events reported.
Last Night’s TV: Embarrassing Bodies, Channel 4; Waking The Dead, BBC1 (Independent)
The voiceover at the start of last night’s Embarrassing Bodies told us that a team of doctors would be crossing the country in a mobile clinic “leaving no orifice unprobed” and within moments of them arriving in Leeds it was clear that the voiceover wasn’t kidding, as a camera took us on a voyage […]
keep looking »